CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: December-17-13
Credit Expiration Date: December-17-14


Michael York, MD
Assistant Professor in Medicine
Section of Rheumatology
Boston University Medical Campus
Boston, MA

Naomi Amudala, MSN, RN, FNP-BC
Clinical Instructor and Nurse Practitioner
Vasculitis Center/Rheumatology
Boston University School of Medicine
Boston, MA

Tuhina Neogi, MD, PhD
Associate Professor of Medicine and of Epidemiology
Boston University School of Medicine
Boston, MA

Credit Hours



Mobile + Online on RealCME

Program Description

Achieving RA Treatment Goals: Maximizing Safety and Efficacy
A 2-part Curriculum

Part 1: ThePractice
Sandy Visit 1: A 33-year-old woman starting treatment for newly diagnosed rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune condition characterized by chronic inflammation primarily affecting the lining of the joints but also affecting other organs. Patients who have RA may suffer from loss of functional capacity as their disease progresses, and many experience reduced health-related quality of life. RA treatment goals are aimed at controlling pain and inflammation and, ultimately, slowing the progression of joint destruction and disability. This activity will help clinicians improve outcomes in patients with RA by expanding their skills to 1) initiate treatment as early as possible with a DMARD, 2) appropriately utilize the full range of medications available for the management of RA, and 3) ensure appropriate, individualized treatment targets are reached according to new ACR therapy guidelines.

This activity is an interactive case-based experience that approximates the assessment and decision-making (prioritization, diagnostic and therapeutic options) inherent in day-to-day patient care. The format integrates interaction among faculty members who represent different members of the health care team and who provide learners with information and commentary that can be immediately applied to their practice.

Program Developer/Facilitator

This activity is jointly provided by Global Education Group and MCM Education

Target Audience

This activity is designed for rheumatologists and other clinicians who treat patients with RA.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss methods for utilizing RA therapies in a way that maximizes both safety and efficacy.
  2. Outline barriers to using available RA therapies to achieve optimal disease control.
  3. Discuss RA treatment goals and the clinical implications of seeking a state of clinical remission as a primary target for treatment of RA.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Michael York, MD: Nothing to disclose
Naomi A. Amudala, MSN, RN, FNP-BC: Nothing to disclose
Tuhina Neogi, MD, PhD: Nothing to disclose

Planning Committee Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to Disclose
Amanda Glazar, PhD: Nothing to disclose
Anne Jacobson (MCM Education writer): Nothing to disclose

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MCM Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit(s). A statement of credit will be available to print from your user history page.

- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

30 minutes

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Commercial Support Statements

This continuing medical education activity is supported by independent educational grants from AbbVie, Inc. and Amgen, Inc.

Certificate Fee



This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu